Literature DB >> 10577596

Emerging ciprofloxacin-resistant Pseudomonas aeruginosa.

N A Chaudhry1, H W Flynn, T G Murray, H Tabandeh, M O Mello, D Miller.   

Abstract

PURPOSE: To report a clinical series of ciprofloxacin-resistant ocular isolates of Pseudomonas aeruginosa from a tertiary care ophthalmic center.
METHODS: Review of in vitro sensitivities of all ocular isolates of P. aeruginosa be tween July 1991 and September 1998. In vitro resistance was defined as a minimum inhibitory concentration of 4 or more microg per ml.
RESULTS: Nine of 423 ocular isolates of P. aeruginosa showed in vitro resistance to ciprofloxacin. From 1991 to 1994, 0.44% (1/227) of ocular isolates were resistant to ciprofloxacin, whereas from 1995 to 1998, 4.1% (8/ 196) of ocular isolates showed in vitro resistance (P = .014).
CONCLUSIONS: Ciprofloxacin-resistant P. aeruginosa has been identified in recent clinical ocular specimens. Ciprofloxacin resistance among ocular isolates of P. aeruginosa is a local and worldwide concern.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577596     DOI: 10.1016/s0002-9394(99)00196-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

Review 1.  Topical antibiotics for acute bacterial conjunctivitis: a systematic review.

Authors:  A Sheikh; B Hurwitz
Journal:  Br J Gen Pract       Date:  2001-06       Impact factor: 5.386

2.  Overview: Initial antimicrobial therapy for microbial keratitis.

Authors:  M Daniell
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

3.  Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops.

Authors:  Mahendra Singh Rathore; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-07-07       Impact factor: 3.246

4.  Diphosphonium ionic liquids as broad-spectrum antimicrobial agents.

Authors:  George A O'Toole; Michel Wathier; Michael E Zegans; Robert M Q Shanks; Regis Kowalski; Mark W Grinstaff
Journal:  Cornea       Date:  2012-07       Impact factor: 2.651

5.  Ciprofloxacin as ocular liposomal hydrogel.

Authors:  Khaled Mohamed Hosny
Journal:  AAPS PharmSciTech       Date:  2010-02-12       Impact factor: 3.246

6.  An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite.

Authors:  David Granet; Steven J Lichtenstein; Bruce Onofrey; James A Katz
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis.

Authors:  J A Lomholt; M Kilian
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

8.  Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Authors:  Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Durga S Borkar; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Ophthalmic Epidemiol       Date:  2013-05-10       Impact factor: 1.648

9.  [Effectiveness of initial antibiotic therapy for treatment of contact lens-related bacterial keratitis].

Authors:  B Steger; L Speicher; W Philipp; T Gasser; E Schmid; N Bechrakis
Journal:  Ophthalmologe       Date:  2014       Impact factor: 1.059

10.  In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.

Authors:  Regis P Kowalski; Tyler A Kowalski; Robert M Q Shanks; Eric G Romanowski; Lisa M Karenchak; Francis S Mah
Journal:  Cornea       Date:  2013-06       Impact factor: 2.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.